PER 0.00% 10.5¢ percheron therapeutics limited

Ann: Phase IIb study of ATL1102 in DMD completes recruitment, page-15

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 4,696 Posts.
    lightbulb Created with Sketch. 1091
    Great news.

    Now for the cornerstone partner.

    Way too early to sell the farm...but you just never know how desperate Big Pharma is for pipeline, considering ATL has potential beyond just DMD.

    Now the tox study is complete, wonder if the MS program gets dusted off too?

    .
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.